FDA Approves Retevmo® for RET-Mutated Lung, Thyroid Cancers
The U.S. Food and Drug Administration approved Retevmo® (selpercatinib) for three types of RET-mutated cancer: adults with metastatic RET-fusion-positive non-small cell lung cancer (NSCLC); adult...
FDA Approves Targeted Treatment for Lung Cancer Along with Companion Diagnostic
The U.S. Food and Drug Administration (FDA) approved Tabrecta™ (capmatinib) for adults with metastatic non-small cell lung cancer (NSCLC) with the MET exon 14...
Addition of Tislelizumab to Chemotherapy in Frontline Setting Improves Survival for Lung Cancer
Frontline tislelizumab plus chemotherapy significantly improved progression-free survival (primary endpoint) compared with chemotherapy alone in patients with non-squamous non-small cell lung cancer (NSCLC), according to...
Are Harms and Benefits of Lung Cancer Screening Thoroughly Reported on Websites?
A study of lung cancer screening programs websites found that they tend to “lack balance” in their portrayal of potential harms and benefits associated...
COPD Associated with Lung Cancer, Even in Those Who Have Never Smoked
A study published in Thorax found that patients with chronic obstructive pulmonary disease (COPD) who have never smoked have a higher risk of lung...
FDA Approves Imfinzi® Combination to Treat Extensive-Stage Lung Cancer
The U.S. Food and Drug Administration approved Imfinzi® (durvalumab) in combination with etoposide plus either carboplatin or cisplatin as first-line treatment for adults with extensive-stage small...
People Living in Rural Areas, Uninsured or on Medicaid Less Likely to Receive Necessary...
Patients living in rural areas or who are on Medicaid or uninsured are less likely to receive chemotherapy for Non-small cell lung cancer (NSCLC),...
